Latest Headlines

  1. CSafe Global Celebrates Open House At New Basel Service Center

    CSafe Global announced the opening of a new full service centre serving the Basel, Switzerland area. The recently opened service centre is a new location for Airplane Equipment Services (AES).

  2. Almirall Closes $15M Strategic Investment In Suneva Medical

    Almirall, the global pharmaceutical company based in Barcelona, has announced the closing of a $15M in Series C equity investment in Suneva Medical, Inc., an innovative aesthetics leader that markets Bellafill.

  3. FDA Accepts OPKO’s New Drug Application For Rayaldee

    OPKO Health, Inc. recently announced that the U.S. Food and Drug Administration (FDA) has accepted for review OPKO’s New Drug Application (NDA) for calcifediol modified-release capsules (proposed trade name, Rayaldee).

  4. 3SBio Acquires Zhejiang Wansheng Pharmaceutical

    3SBio Inc., (HKEX:1530) ("3SBio" or 'the Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it has acquired the entire equity interest in Zhejiang Wansheng Pharmaceutical Co., Ltd ("Zhejiang Wansheng") a limited liability company incorporated in the PRC for an aggregate consideration of RMB 528 million.

  5. CluePoints Receives €6M Growth Investment

    CluePoints, a leading software provider of risk-based monitoring (RBM) solutions for clinical trials, has recently announced that it has secured a €6million investment to support its future growth, technology innovation and expansion.

  6. Cardiome Submits Supplemental New Drug Submission (sNDS) For AGGRASTAT To Health Canada

    Cardiome Pharma Corp. recently announced that it has submitted a Supplemental New Drug Submission (sNDS) to Health Canada's Therapeutic Products Directorate for AGGRASTAT (tirofiban hydrochloride).

  7. Propeller Health Receives FDA Clearance For The Propeller Platform In Association With Boehringer Ingelheim’s Respimat Inhaler And GlaxoSmithKline’s Diskus Inhaler

    Propeller Health, the FDA-cleared digital health solution for chronic respiratory disease, recently announced U.S. Food and Drug Administration 510(k) clearance to market its Propeller platform in association with medications using GlaxoSmithKline’s Diskus dry powder inhaler (DPI) device for asthma and chronic obstructive pulmonary disease (COPD).

  8. Critical Path Institute Establishes The Global Pediatric Clinical Trials Network Pre-Launch Consortium

    The Critical Path Institute (C-Path), a pioneering non-profit organization dedicated to accelerating the pace and reducing the costs of medical product development by facilitating unique partnerships among a wide range of stakeholders, has formed a new consortium, the Global Pediatric Clinical Trials Network Pre-Launch Consortium (“Pre-Launch Consortium”).

  9. Lysogene and Alcyone Lifesciences Enter a Collaboration for Mucopolysaccharidosis Type IIIA (MPS IIIA)

    Lysogene and Alcyone Lifesciences enter into a collaboration for mucopolysaccharidosis type IIIA (MPS IIIA). The collaboration combines the companies’ expertise in proprietary recombinant adeno-associated virus (rAAV) based gene therapy and MEMS based targeted drug delivery

  10. Marken Launches Investigator Survey Call Center

    Marken, the leading clinical logistics organization (CLO), has launched a survey call center to contact clinical investigator sites throughout Latin America.

Newsletter Signup
By clicking Sign Me Up, you agree to our Terms and that you have read our Privacy Policy.